Found: 101
Select item for more details and to access through your institution.
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 9, p. 2539, doi. 10.1007/s13555-024-01245-6
- By:
- Publication type:
- Article
Human Mast Cells Upregulate Cathepsin B, a Novel Marker of Itch in Psoriasis.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 17, p. 2177, doi. 10.3390/cells12172177
- By:
- Publication type:
- Article
Distress, misperceptions, poor coping and suicidal ideation in psoriatic arthritis: a qualitative study.
- Published in:
- Rheumatology, 2016, v. 55, n. 6, p. 1047, doi. 10.1093/rheumatology/kew009
- By:
- Publication type:
- Article
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.
- Published in:
- Rheumatology, 2014, v. 53, n. 2, p. 213, doi. 10.1093/rheumatology/ket260
- By:
- Publication type:
- Article
The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of Psoriasis.
- Published in:
- Molecular Diagnosis & Therapy, 2010, v. 14, n. 2, p. 81, doi. 10.1007/BF03256357
- By:
- Publication type:
- Article
Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomization.
- Published in:
- Rheumatology, 2023, v. 62, n. 3, p. 1272, doi. 10.1093/rheumatology/keac403
- By:
- Publication type:
- Article
Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene.
- Published in:
- Human Molecular Genetics, 2008, v. 17, n. 13, p. 1938, doi. 10.1093/hmg/ddn091
- By:
- Publication type:
- Article
Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.
- Published in:
- Nature Communications, 2015, v. 6, n. 7, p. 7741, doi. 10.1038/ncomms8741
- By:
- Publication type:
- Article
Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.
- Published in:
- Nature Communications, 2015, v. 6, n. 2, p. 6046, doi. 10.1038/ncomms7046
- By:
- Publication type:
- Article
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2077, doi. 10.1007/s13555-024-01210-3
- By:
- Publication type:
- Article
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3031, doi. 10.1007/s13555-023-01054-3
- By:
- Publication type:
- Article
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2839, doi. 10.1007/s13555-023-01034-7
- By:
- Publication type:
- Article
Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 245, doi. 10.1007/s13555-022-00846-3
- By:
- Publication type:
- Article
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 8, p. 1777, doi. 10.1007/s13555-022-00760-8
- By:
- Publication type:
- Article
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 3, p. 787, doi. 10.1007/s13555-022-00687-0
- By:
- Publication type:
- Article
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 561, doi. 10.1007/s13555-021-00679-6
- By:
- Publication type:
- Article
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1657, doi. 10.1007/s13555-021-00585-x
- By:
- Publication type:
- Article
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1551, doi. 10.1007/s13555-021-00570-4
- By:
- Publication type:
- Article
Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 1, p. 73, doi. 10.1007/s13555-019-00337-y
- By:
- Publication type:
- Article
Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis.
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 6, p. 1255, doi. 10.1007/s13555-020-00434-3
- By:
- Publication type:
- Article
Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 1, p. 73, doi. 10.1007/s13555-019-00337-y
- By:
- Publication type:
- Article
The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature.
- Published in:
- Dermatology & Therapy, 2019, v. 9, n. 2, p. 373, doi. 10.1007/s13555-019-0290-5
- By:
- Publication type:
- Article
Topical Treatments for Scalp Psoriasis.
- Published in:
- Drugs, 2008, v. 68, n. 16, p. 2293, doi. 10.2165/0003495-200868160-00003
- By:
- Publication type:
- Article
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 5, p. 2256, doi. 10.1007/s12325-022-02065-w
- By:
- Publication type:
- Article
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 10, p. 5253, doi. 10.1007/s12325-021-01836-1
- By:
- Publication type:
- Article
PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis.
- Published in:
- Advances in Therapy, 2020, v. 37, n. 11, p. 4730, doi. 10.1007/s12325-020-01497-6
- By:
- Publication type:
- Article
Mapping DNA interaction landscapes in psoriasis susceptibility loci highlights KLF4 as a target gene in 9q31.
- Published in:
- BMC Biology, 2020, v. 18, n. 1, p. 1, doi. 10.1186/s12915-020-00779-3
- By:
- Publication type:
- Article
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study.
- Published in:
- Arthritis & Rheumatology, 2022, v. 74, n. 12, p. 1959, doi. 10.1002/art.42280
- By:
- Publication type:
- Article
Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 8, p. 2011, doi. 10.1002/art.39169
- By:
- Publication type:
- Article
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS).
- Published in:
- Dermatologic Therapy, 2023, p. 1, doi. 10.1155/2023/9967747
- By:
- Publication type:
- Article
Precalcaneal Congenital Fibrolipomatous Hamartoma.
- Published in:
- Pediatric Dermatology, 2007, v. 24, n. 1, p. 74, doi. 10.1111/j.1525-1470.2007.00340.x
- By:
- Publication type:
- Article
A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 3, p. 271, doi. 10.1093/bjd/ljad179
- By:
- Publication type:
- Article
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 2, p. 161, doi. 10.1093/bjd/ljad083
- By:
- Publication type:
- Article
O15 Using CRISPR-Cas9 to annotate the TYK2 pathway in psoriasis.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. e10, doi. 10.1093/bjd/ljad174.015
- By:
- Publication type:
- Article
O10 STAT3 activation in peripheral blood MAIT cells is a predictive biomarker of response to biologics targeting the IL-23/IL-17 axis.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. e8, doi. 10.1093/bjd/ljad174.010
- By:
- Publication type:
- Article
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 62, doi. 10.1093/bjd/ljad107
- By:
- Publication type:
- Article
395 Assessing imputation methods with the lebrikizumab clinical trial program.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.020
- By:
- Publication type:
- Article
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 6, p. 749, doi. 10.1093/bjd/ljad035
- By:
- Publication type:
- Article
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 5, p. 618, doi. 10.1093/bjd/ljad004
- By:
- Publication type:
- Article
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 4, p. 542, doi. 10.1093/bjd/ljac109
- By:
- Publication type:
- Article
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 3, p. 330, doi. 10.1093/bjd/ljac089
- By:
- Publication type:
- Article
309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii6, doi. 10.1093/bjd/ljac140.009
- By:
- Publication type:
- Article
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 2, p. 198, doi. 10.1093/bjd/ljac040
- By:
- Publication type:
- Article
Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials*.
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 6, p. 888, doi. 10.1111/bjd.21867
- By:
- Publication type:
- Article
A rapid access clinic for psoriasis: first experiences.
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 3, p. 426, doi. 10.1111/bjd.21242
- By:
- Publication type:
- Article